Background The diagnosis of gastrointestinal (GI) involvement in Kaposi's sarcoma (KS) is important to make because the need for treatment depends on the extent of the disease. Moreover, severe GI lesions can cause serious complications. Endoscopy with biopsy is an extremely useful method to diagnose GI-KS. However, determining the indications for endoscopy is difficult because KS can occur without GI symptoms or cutaneous KS. This study sought to clarify predictive clinical factors for GI-KS and its severity on endoscopy. Methodology/Principal Findings A total of 1,027 HIV-infected patients who underwent endoscopy were analyzed. Sexual behavior, CD4 count, HIV RNA, history of highly active antiretroviral therapy (HAART), GI symptoms, and cutaneous KS were assessed. Endoscopic severity including bulky tumor, ulceration, and number of lesions were evaluated. Thirty-three patients had GI-KS and 46 patients cutaneous KS. Among the GI-KS patients, 78.8% (26/33) had no GI symptoms and 24.2% (8/33) had no cutaneous KS. Univariate analysis identified men who have sex with men (MSM), CD4 <100 cells/μL, HIV RNA ≥10,000 copies/mL, no history of HAART, and cutaneous KS were significantly associated with GI-KS. Among these factors, cutaneous KS was closely related to GI-KS on multivariable analysis. Among patients without cutaneous KS, MSM and CD4 count <100 cells/μL were the only independent clinical factors related to GI-KS. Bulky tumor was significantly associated with CD4 <100 cells/μL and large number of lesions was significantly associated with HIV-RNA ≥10,000 copies/mL. Conclusions To diagnose GI-KS, clinical factors need to be considered before endoscopy. The presence of GI symptoms is not useful in predicting GI-KS. MSM and CD4 count <100 cells/μL are predictive factors among patients without cutaneous KS. Caution should be exercised especially in patients with low CD4 counts or high HIV viral loads as they are more likely to develop severe GI-KS lesions.
References
[1]
Braun M (1982) Classics in oncology. idiopathic multiple pigmented sarcoma of the skin by kaposi. CA: A Cancer Journal for Clinicians 32: 340–347.
[2]
Beral V, Peterman TA, Berkelman RL, Jaffe HW (1990) Kaposi's sarcoma among persons with AIDS: A sexually transmitted infection? Lancet 335: 123–128.
[3]
Chang Y, Cesarman E, Pessin MS, Lee F, Culpepper J, et al. (1994) Identification of herpesvirus-like DNA sequences in AIDS-associated kaposi's sarcoma. Science 266: 1865–1869.
[4]
Buchacz K, Baker RK, Palella FJ Jr, Chmiel JS, Lichtenstein KA, et al. (2010) AIDS-defining opportunistic illnesses in US patients, 1994–2007: A cohort study. AIDS (London, England) 24: 1549–1559.
[5]
Engels EA, Pfeiffer RM, Goedert JJ, Virgo P, McNeel TS, et al. (2006) Trends in cancer risk among people with AIDS in the united states 1980–2002. AIDS (London, England) 20: 1645–1654.
[6]
Biggar RJ, Rabkin CS (1996) The epidemiology of AIDS–related neoplasms. Hematology/oncology Clinics of North America 10: 997–1010.
[7]
Mocroft A, Kirk O, Clumeck N, Gargalianos-Kakolyris P, Trocha H, et al. (2004) The changing pattern of kaposi sarcoma in patients with HIV, 1994–2003: The EuroSIDA study. Cancer 100: 2644–2654.
[8]
Beral V, Bull D, Darby S, Weller I, Carne C, et al. (1992) Risk of kaposi's sarcoma and sexual practices associated with faecal contact in homosexual or bisexual men with AIDS. Lancet 339: 632–635.
[9]
Lodi S, Guiguet M, Costagliola D, Fisher M, de Luca A, et al. (2010) Kaposi sarcoma incidence and survival among HIV-infected homosexual men after HIV seroconversion. Journal of the National Cancer Institute 102: 784–792.
[10]
Gallafent JH, Buskin SE, De Turk PB, Aboulafia DM (2005) Profile of patients with kaposi's sarcoma in the era of highly active antiretroviral therapy. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 23: 1253–1260.
[11]
Stebbing J, Sanitt A, Nelson M, Powles T, Gazzard B, et al. (2006) A prognostic index for AIDS-associated kaposi's sarcoma in the era of highly active antiretroviral therapy. Lancet 367: 1495–1502.
[12]
Dezube BJ (1996) Clinical presentation and natural history of AIDS–related kaposi's sarcoma. Hematology/oncology Clinics of North America 10: 1023–1029.
[13]
Ngendahayo P, Mets T, Bugingo G, Parkin DM (1989) [Kaposi's sarcoma in rwanda: Clinico-pathological and epidemiological aspects]. Bulletin Du Cancer 76: 383–394.
[14]
Danzig JB, Brandt LJ, Reinus JF, Klein RS (1991) Gastrointestinal malignancy in patients with AIDS. The American Journal of Gastroenterology 86: 715–718.
[15]
Laine L, Amerian J, Rarick M, Harb M, Gill PS (1990) The response of symptomatic gastrointestinal kaposi's sarcoma to chemotherapy: A prospective evaluation using an endoscopic method of disease quantification. The American Journal of Gastroenterology 85: 959–961.
[16]
Ioachim HL, Adsay V, Giancotti FR, Dorsett B, Melamed J (1995) Kaposi's sarcoma of internal organs. A multiparameter study of 86 cases. Cancer 75: 1376–1385.
[17]
Krown SE, Testa MA, Huang J (1997) AIDS-related kaposi's sarcoma: Prospective validation of the AIDS clinical trials group staging classification. AIDS clinical trials group oncology committee. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 15: 3085–3092.
[18]
Nasti G, Talamini R, Antinori A, Martellotta F, Jacchetti G, et al. (2003) AIDS-related kaposi's sarcoma: Evaluation of potential new prognostic factors and assessment of the AIDS clinical trial group staging system in the haart era–the italian cooperative group on AIDS and tumors and the italian cohort of patients naive from antiretrovirals. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 21: 2876–2882.
[19]
Friedman SL, Wright TL, Altman DF (1985) Gastrointestinal kaposi's sarcoma in patients with acquired immunodeficiency syndrome. endoscopic and autopsy findings. Gastroenterology 89: 102–108.
[20]
Kahl P, Buettner R, Friedrichs N, Merkelbach-Bruse S, Wenzel J, et al. (2007) Kaposi's sarcoma of the gastrointestinal tract: Report of two cases and review of the literature. Pathology, Research and Practice 203: 227–231.
[21]
Barrison IG, Foster S, Harris JW, Pinching AJ, Walker JG (1988) Upper gastrointestinal kaposi's sarcoma in patients positive for HIV antibody without cutaneous disease. British Medical Journal (Clinical Research Ed.) 296: 92–93.
[22]
Yoshida EM, Chan NH, Chan-Yan C, Baird RM (1997) Perforation of the jejunum secondary to AIDS-related gastrointestinal kaposi's sarcoma. Canadian Journal of Gastroenterology = Journal Canadien De Gastroenterologie 11: 38–40.
[23]
Nagata N, Yazaki H, Oka S (2011) Kaposi's sarcoma presenting as a bulky tumor mass of the colon. Clin Gastroenterol Hepatol 9: A22.
[24]
Lingenfelser T, Daiss W, Overkamp D, Weber P (1994) Successful monochemotherapy of extensive gastrointestinal kaposi's sarcoma with bowel obstruction in acquired immunodeficiency syndrome. Zeitschrift Fur Gastroenterologie 32: 688–690.
[25]
Carratala J, Lacasa JM, Mascaro J, Torras JT (1992) AIDS presenting as duodenal perforation due to kaposi's sarcoma. AIDS (London, England) 6: 241–242.
[26]
Ravalli S, Vincent RA, Beaton H (1990) Primary kaposi's sarcoma of the gastrointestinal tract presenting as acute appendicitis. The American Journal of Gastroenterology 85: 772–773.
[27]
Weprin L, Zollinger R, Clausen K, Thomas FB (1982) Kaposi's sarcoma: Endoscopic observations of gastric and colon involvement. Journal of Clinical Gastroenterology 4: 357–360.
[28]
Kahn HJ, Bailey D, Marks A (2002) Monoclonal antibody D2–40, a new marker of lymphatic endothelium, reacts with kaposi's sarcoma and a subset of angiosarcomas. Modern Pathology: An Official Journal of the United States and Canadian Academy of Pathology, Inc 15: 434–440.
[29]
Rosado FG, Itani DM, Coffin CM, Cates JM (2012) Utility of immunohistochemical staining with FLI1, D2–40, CD31, and CD34 in the diagnosis of acquired immunodeficiency syndrome-related and non-acquired immunodeficiency syndrome-related kaposi sarcoma. Archives of Pathology & Laboratory Medicine 136: 301–304.
